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Rheumatoid arthritis (RA) is a systemic autoimmune
disease manifesting in joint destruction. The recognized
hallmark of RA pathogenesis is the involvement of
immune cells which produce many mediators
potentiating an inflammatory environment. RA
synovial fibroblasts (RASFs) contribute significantly to
disease progression by initiating and regulating many
pathways of joint destruction. Detailed molecular
insights into RASF biology may lead to identification of
important therapeutic targets. The discovery of common
molecular targets for joint resident and inflammatory
cells may help to develop the most effective therapeutic
strategy. One such pathway includes semaphorin 4A as
reported in a recent article in Arthritis Research & Therapy.cells (reviewed in [5]). The multiple and complex waysRheumatoid arthritis synovial fibroblasts (RASFs) produce
a variety of cytokines, chemokines, and matrix metallopro-
teinases (MMPs) which potentiate the effects of inflamma-
tory and immune cells in rheumatoid arthritis (RA). In a
recent article in Arthritis Research & Therapy, Wang and
colleagues [1] report new findings on semaphorin 4A
(Sema4A) in disease. They examined the expression and
function of Sema4A in synovial tissues and in RASFs ob-
tained from patients with a confirmed RA diagnosis.
Sema4A belongs to a family of glycoproteins that were
originally found in the nervous system and that function
as axon guidance molecules. The pioneering semaphorin
immunology research by Kumanogoh and colleagues [2]
identified Sema4A expression on antigen-presenting cellsCorrespondence: semaplex@comcast.net
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acts as a co-stimulator of T-cell activation in vitro and
potentiator of antigen-specific T-cell generation in vivo
[2, 3]. In vitro, Sema4A-Fc increased antigen-dependent
T-cell proliferation and interleukin (IL)-2 production
whereas anti-Sema4A Ab inhibited allogeneic response
in T cell–dendritic cell mixed lymphocyte reactions.
Sema4A interacts with T-cell immunoglobulin and
mucin domain-2 (Tim-2) predominantly expressed on
T helper (Th)2 cells [2]. The recent study by Delgoffe
and colleagues [4] stressed a critical role of Sema4A-
neuropilin-1 interaction in regulatory T (Treg) cell dif-
ferentiation, survival, stability, and function. Additionally,
Sema4A engages several Plexin family members—namely
Plexin D1, Plexin B1, and Plexin B2—expressed on non-
immune (epithelial or endothelial or both) and immune
that Sema4A interacts with its receptors have been shown
to play important roles in several physiological and patho-
logical conditions (reviewed in [5]). Targeted disruption of
Sema4A in animal models led to impaired antigen-specific
T-cell generation and cytokine production [2]. The aug-
mented severity of systemic allergic inflammatory responses
was found in ovalbumin-treated Sema4A-deficient mice
and was associated with increased Treg cell numbers,
whereas Th1/interferon-gamma response was not affected
[6, 7]. Rennert and colleagues [8] have shown that Tim-2-
deficient mice exhibited increased lung inflammation and
Th2 cytokine production in response to allergen. Hence,
the opposite effects of Sema4A in autoimmune and aller-
gic inflammatory diseases suggest that Sema4A promotes
Th1 cell and suppresses Th2 cell responses. However,
recombinant human Sema4A (rhSema4A) effectively inhib-
ited already established allergic lung inflammation [9],
and bone marrow chimeric mice demonstrated an equal
importance of Sema4A expression on lung resident cellsdistributed under the terms of the Creative Commons Attribution 4.0
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disease manifestation [8]. Thus, the function of Sema4A
in autoimmune and allergic diseases is complex and af-
fects many immune and non-immune cells.
Wang and colleagues [1] demonstrated significantly
higher levels of Sema4A mRNA and protein expression
in synovial tissues of RA patients as compared with those
with osteoarthritis. Moreover, the levels of secreted
Sema4A positively correlated with disease activity score.
Invasive ability of RASF was potentiated by rhSema4A
and blocked with Sema4A small interfering RNA (siRNA).
Pro-invasion activity of Sema4A was supported by the
data on Sema4A-dependent induction of MMP-3 and
MMP-9 expression in RASFs. Furthermore, there is a
positive stimulatory Sema4A-nuclear factor-kappa-B
(NF-κB) loop as the silencing of p50 or p65 with siRNA
constructs led to inhibition of Sema4A expression and
rhSema4A treatment upregulated NF-κB phosphorylation
in cells. In addition, rhSema4A-dependent IL-6 produc-
tion in RASFs was attenuated by a specific NF-κB inhibi-
tor. The induction of IL-6 by rhSema4A in RASFs was
significantly inhibited by silencing Plexin B1 and partially
inhibited by silencing Plexin D1 and TIM-2, thus clearly
demonstrating the different levels of involvement of three
Sema4A receptors in RA pathogenesis relative to RASF
activation and function. The lipopolysaccharide-induced
release of other proinflammatory cytokines, namely tumor
necrosis factor-alpha and IL-1β, in TH1 cell line was sig-
nificantly promoted by rhSema4A. Importantly, all three
cytokines are considered to be the critical regulators of
RA pathogenesis and their inhibition had demonstrated
the reverse effects on disease progression and significant
improvement of disease activity scores [10]. In addition to
all of the above, the detected overexpression of soluble
Sema4A in RA patients’ synovial fluids and serum may
prove the potential of Sema4A as a diagnostic and prog-
nostic marker for disease initiation, progression, and thera-
peutic intervention.
Taken together, the data presented by Wang and col-
leagues [1] pave the way for further investigations of
Sema4A in autoimmune diseases, including RA, and pro-
vide evidence for its therapeutic potential. The multifaceted
activity of Sema4A in coordination of numerous immuno-
logic and pathologic mechanisms involved in RA requires
their careful and detailed individual examination.
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